Medline has put forward terms for an absolutely massive IPO, which could see the medical device manufacturing and ...

GSK is officially cutting ties with Ideaya Biosciences, handing back two clinical programs as part of the termination of a ...

After announcing plans to split up the company near the top of this year, Teleflex said it has found new homes for its ...

The FDA has cleared the first artificial intelligence (AI) drug development tool to help evaluate fatty liver disease in ...

OSE Immunotherapeutics is prioritizing its lung cancer med Tedopi and shifting the strategy for its ulcerative colitis (UC) ...

Exicure’s investigational small molecule succeeded in mobilizing key blood-forming cells in almost 90% of patients in a phase ...

Novartis has tapped up an AI-enabled British biotech for a $1.7 billion biobucks deal to discover new targets for ...

The FDA is raising the bar for approval of CAR T-cell therapies in oncology. | The FDA is raising the bar for approval of CAR ...

Novartis is divulging details from ianalumab’s summertime | Novartis is divulging details from ianalumab’s phase 3 win in a rare autoimmune blood disorder, and the data suggest the treatment could del ...

Pfizer’s recent bidding war for an obesity biotech clearly hasn’t satiated the pharma’s appetite for new GLP-1 therapies—at least going by ...

The Chinese biotech evaluated three different once-daily doses of its oral GLP-1 agonist, dubbed ASC30, in a phase 2 study of ...

Dr. Reddy’s Laboratories is paying $20 million upfront for the rights to Immutep’s phase 3-stage LAG-3 candidate in certain ...